Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Is Select Medical Holdings Corporation (SEM) the Best High-Flying Stock to Buy?

We recently compiled a list of the 10 High-Flying Stocks to Buy Now. In this article, we are going to take a look at where Select Medical Holdings Corporation (NYSE:SEM) stands against the other high-flying stocks.

The equity markets are priced for a soft landing. This means that even the fear of a mild recession might trigger a significant equity-market correction. The broader economic data aids the soft-landing thesis, but a slowdown consistent with soft landing might still lead to a downturn, explains Chief Investment Strategist of Russell Investments. As of now, a soft landing appears to be a more likely outcome. Inflation continues to decline, growth in wages has been moderating, and labor-market pressures are cooling. Importantly, the US Fed started easing before the clear signs of economic stress emerged.

Factors Driving Volatility- Caution for Investors

As per Allianz Global Investors, the interest rate cut by the US Fed in September made a watershed moment for the broader markets. While the opportunities for investors might reverse overnight, the company believes that it marks the beginning of the end of a period in which tech stocks and cash (or cash-like instruments) were the go-to instruments for market players.

Overall, the firm remains optimistic about the months ahead, while admitting that this period is a period of below-potential growth in which downside risks are expected to naturally increase. Geopolitics might act as a continuing source of volatility as and when events unfold in the Middle East and Ukraine. This can be a threat to another potential surge in energy prices. The risk of the US election looms large, with the policies of the winner expected to leave a lasting market impact. There are risks in Europe, where France and Germany are impacted by domestic issues while growth and financial stability remain vulnerable. The investment management firm believes that there is a danger of broader instability in the eurozone, with implications for bond markets.

The equity markets anticipate an aggregate of 135 bps of global cuts over the next year as compared to only 75 bps at the end of June. The firm expects that a significant chunk is expected in the US, more than what was expected in the soft-landing scenario. This might lead to a repricing of expectations, resulting in volatility.

Amidst such uncertainties, market investors are required to be focused on quality and growth companies. With global economic growth decelerating, this should not be treated as a bearish signal for the broader equities. As inflation and rates come down, the path is expected to be positive for quality and growth, with the investment management firm expecting such styles to outperform over the coming months. Even though the performance of the global economy remains highly dependent on whether the balance between rates, growth, and prices is achieved, some signs point towards a favorable outcome.

Since the final part of the year might see some volatility, looking selectively to some defensive options will ensure that portfolios remain as balanced as possible.

What Lies Ahead?

The technology stocks led the equity market rally for much of 2024, with investors seeing the AI euphoria in full effect. However, investors continue to question whether this enthusiasm has been exhausted or if there is any heat left. BlackRock believes that the momentum in technology is expected to continue and that the summer setback was just temporary. Having said that, the asset manager sees a greater differentiation throughout technology stocks.

The firm believes that earnings growth is expected to remain healthy for the technology sector broadly, as a result of the build-out of AI and a commitment to cost prudence from tech firms.

Morningstar believes that the rotation into small-cap and value stocks should continue to see a decent rally as each remains undervalued on an absolute basis and relative to the market valuation.

Our methodology

To list 10 High-Flying Stocks to Buy Now, we conducted an extensive online search and sifted through online rankings and different screeners. After extracting the list of 20-30 stocks, we filtered out the stocks having the highest upside potential and which have performed well on a YTD basis. Finally, we ranked the stocks according to their upside potential, as of October 1.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

A medical staff analyzing data in an occupational health center.

Select Medical Holdings Corporation (NYSE:SEM)

% Increase on a YTD Basis: ~42%

Expected Upside Potential: 32.28%

Number of Hedge Fund Holdings: 20

Select Medical Holdings Corporation (NYSE:SEM) operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the US.

On the YTD basis, the company’s stock saw an increase of ~42%, serving as an affirmation of its strong market position and potential for future growth. Select Medical Holdings Corporation (NYSE:SEM) wrapped up an IPO of Concentra on July 26 and still has a majority stake of ~82.23%. However, it has plans to distribute the remaining interest to shareholders in a year. Select Medical Holdings Corporation (NYSE:SEM) continues to advance its growth strategy by opening new facilities and reporting revenue increases in its hospital divisions.

Furthermore, Select Medical Holdings Corporation (NYSE:SEM) witnessed labor cost improvement, with lower RN agency costs and sign-on bonuses. The company continues to focus on clinical efficiencies and scheduling improvements. Also, wage rates for permanent staff in critical illness hospitals have been stabilizing to pre-COVID-19 levels.

Select Medical Holdings Corporation (NYSE:SEM)’s strategic developments and operational efficiencies have placed it well for continued growth. With hospital divisions surpassing revenue expectations and effective management of labor costs, Select Medical Holdings Corporation (NYSE:SEM) has been tackling the challenges of the broader healthcare industry while pursuing expansion strategies.

For FY 2024, the company anticipates revenue of between $6.9 billion – $7.1 billion and adjusted EBITDA of between $845 million – $885 million. Analysts at Benchmark reissued a “Buy” rating on the shares of Select Medical Holdings Corporation (NYSE:SEM), setting a price objective of $48.00 on 6th September.

As per Insider Monkey’s Q2 2024 database, 20 hedge funds were long Select Medical Holdings Corporation (NYSE:SEM).

Overall SEM ranks 7th on our list of the high-flying stocks to buy now. While we acknowledge the potential of SEM as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for a deeply undervalued AI stock that is more promising than SEM but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’

Disclosure: None. This article is originally published at Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by 15% and offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $6.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on our Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $6.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

NYSE-traded tiny biotech firm has a revolutionary offering to the medical world since antibiotics!

Tiny NYSE-traded biotech firm is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

The Company’s virus-specific nanoviricides have been created against important viruses such as HIV, Influenza and Bird Flu by choosing highly virus-specific ligands.

Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is also developing broad-spectrum nanoviricides to combat several neglected tropical diseases, such as Dengue, Rabies, and Ebola/Marburg.

Its one lead drug alone potentially addresses a $2.5 to $4.3 Billion market.

Click to continue reading…